Chonluten — Research, Dosing & Price Guide

Chonluten is a bioregulatory tripeptide (Glu-Asp-Gly) developed at the Khavinson Institute that targets bronchial mucosa and gastrointestinal epithelium. It normalizes mucosal barrier function, supports secretory immune defenses, and maintains the epithelial integrity essential for both respiratory and digestive health. Its dual-tissue targeting makes it particularly relevant for aging individuals experiencing concurrent decline in both respiratory and GI mucosal function.

Chonluten modulates gene expression in mucosal epithelial cells of both the respiratory and gastrointestinal tracts. The tripeptide Glu-Asp-Gly interacts with tissue-specific chromatin regions to promote the expression of: secretory IgA (the primary immunoglobulin of mucosal immunity); mucin glycoproteins (MUC5AC in airways, MUC2 in intestine) that form the protective mucus layer; tight junction proteins (claudins, occludin, ZO-1) that maintain epithelial barrier integrity; and trefoil factors that promote mucosal healing. By restoring these gene expression patterns toward youthful levels, Chonluten helps maintain the barrier function that naturally degrades with aging — reducing susceptibility to respiratory infections, improving mucociliary clearance, and supporting intestinal barrier integrity (reducing 'leaky gut').

• Improved mucosal barrier function markers (tight junction protein expression, transepithelial electrical resistance) in aged mucosal tissue models.
• Enhanced secretory IgA production in bronchial and intestinal tissue samples treated with Chonluten in Khavinson Institute studies.
• Tripeptide confirmed to interact with specific gene promoter sequences in pulmonary and intestinal epithelium using molecular biology assays.
• Reduced frequency of respiratory infections in elderly cohorts receiving seasonal bioregulator protocols including Chonluten.
• Part of the validated Khavinson bioregulatory peptide family with extensive safety data from 30+ years of clinical practice.

• Standard dose: 10 mg subcutaneous injection daily.
• Typical cycle: 10–20 days.
• Repeat every 3–6 months, ideally before respiratory infection season.
• Can be combined with Bronchogen for enhanced respiratory support (Chonluten covers both respiratory and GI mucosa, while Bronchogen is bronchial-specific).
• Oral capsule formulations available at higher doses for those preferring non-injectable administration.
• No food timing restrictions.

Known Side Effects

• Injection site reactions — mild and uncommon.
• No significant adverse events reported.
• No GI disturbance despite targeting GI epithelium — the mechanism is restorative, not stimulatory.
• No immune overstimulation — the peptide normalizes rather than amplifies immune responses.
• Short cycle length limits exposure.

Safety Profile

Chonluten has the characteristic safety profile of Khavinson bioregulator peptides — excellent tolerability across decades of clinical use in elderly populations. The tripeptide is rapidly metabolized, produces no systemic pharmacological effects, and works through gentle epigenetic restoration rather than forceful modulation. No contraindications beyond hypersensitivity and pregnancy/breastfeeding. No drug interactions. Safe for use alongside respiratory medications (bronchodilators, inhaled corticosteroids) and GI medications (PPIs, H2 blockers).

Days 1–10: No immediate perceptible effects. Epigenetic modulation of mucosal epithelial gene expression is initiating. Days 11–20: Molecular changes are establishing. Subtle improvements in respiratory comfort or digestive ease may begin for some users. Weeks 3–12 (post-cycle): Benefits become more apparent — improved breathing comfort, reduced susceptibility to upper respiratory infections, better digestive tolerance. Mucosal barrier improvements persist after the cycle ends. Months 3–6: Effects maintain throughout the inter-cycle period. Repeat cycles sustain and build upon the benefits cumulatively.

Prices sourced from peptides.gg marketplace. Prices may vary.